Trials / Completed
CompletedNCT00544687
Phase I Study of Topical CRx-191 in Normal Healthy Volunteers
A Phase I, Single-Center, Randomized, Vehicle and Active-Controlled Study to Assess and Compare the Atrophy-Causing Potential of Topical CRx-191 Formulations in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Zalicus · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor- alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CRx-191 | topical (mometasone furoate + nortriptyline HCl) |
| DRUG | mometasone furoate | topical mometasone furoate |
| DRUG | nortriptyline HCl | topical nortriptyline HCl |
| DRUG | Karison® Creme | topical Karison® Creme (clobetasol-17-propinate 0.05%) |
| DRUG | Vehicle | topical (placebo) |
Timeline
- Start date
- 2007-09-01
- Completion
- 2007-11-01
- First posted
- 2007-10-16
- Last updated
- 2007-11-15
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00544687. Inclusion in this directory is not an endorsement.